dacomitinib sold brand name vizimpro medication treatment nonsmallcell lung carcinoma nsclc selective irreversible inhibitor dacomitinib advanced several phase iii clinical trialswhen january results first trials disappointing failure meet study additional phase iii trials results trial comparing dacomitinib gefitinib nsclc driven mutated egfr dacomitinib approved medical use united states september japan european union treatment nonsmall cell lung cancer epidermal growth factor receptor egfr gene mutation antineoplastic immunomodulatory drug article stub help wikipedia expanding ithttpsenwikipediaorgwikidacomitinib